In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)

In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium.  The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, entered into illegal reverse-payment agreements with certain generic manufacturers (namely Ranbaxy, Teva, and Dr. Reddy’s) to delay the entry of more affordable generic Nexium.  The class also alleges that AstraZeneca brokered a single conspiracy among all 3 generic manufacturers to achieve that same illegal delay in generic competition.  The case has proceeded through dispositive motions practice and is scheduled for trial in October of 2014.  Peter Kohn is on the trial team for this case.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.


Filed on 08/27/2012


1617 JFK Boulevard, Suite 1550

19103 Philadelphia, Pennsylvania

Phone (215) 277-5770

Fax (215) 277-5771


Joseph T. Lukens Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331


1901 Avenue of the Stars Suite 1060
Los Angeles, California 90067
(424) 256-2884
(424) 256-2885


3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534


1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania